KYOTO-SEMICONDUCTOR
26.5.2020 07:02:11 CEST | Business Wire | Press release
In the forty years since the company’s founding, Kyoto Semiconductor Co., Ltd., Tsuneo Takahashi, President and CEO, and headquartered in Fushimi Ward, Kyoto, has led the industry with optical solutions built from world-standard technologies and with Japanese quality and attention to production detail. They have announced the development of a Two-Wavelength Photodiode, the KP-2 Two-tone Photodiode KPMC29, in the industry’s smallest class and capable of being surface-mounted, with silicon and indium-gallium-arsenide photodiodes, with photosensitivity for a wide range of wavelengths, from 400 to 1,700 nm, arrayed along the same light axis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005017/en/
This broadband sensitivity, together with a smaller package that is 1/8 the volume ratio of older Kyoto Semiconductor products, can be used in the healthcare field for applications that include medical biometric monitoring like pulse oximeters as well as wearable activity monitors. Because it is also possible to independently produce photocurrent signals from the silicon and indium-gallium-arsenide photodiodes, measuring the photocurrent ratio will allow for its use as a radiation thermometer that can measure temperatures without direct contact with hot object.
Development Background
Spectroscopic analysis technology, that allows for the identification of objects and their characteristics without needing direct contact with those objects, by reflecting light of those objects and measuring the degrees of transmission and reflection, is increasingly needed in a wide range of fields, including medicine, production, and security. Spectroscopic analysis relies on two factors for successful use in identifying a wide range of objects: a wider range of wavelengths, or colors, for the source wavelengths, and a wider range of sensitivity for those wavelengths with the photodiode end. There is also a need for smaller products, compared to existing corded-lead products, for use with medical equipment or wearable devices that can be worn directly on the human body.
Development was therefore undertaken to meet these product needs.
Product Characteristics
-
A wider range of wavelength sensitivity (400~1,700nm).
To expand the wavelength range, we layered both silicon photodiodes, which are sensitive to shorter wavelengths, and indium-gallium-arsenide photodiodes, which are sensitive to longer wavelengths, along the same light axis. -
A compact surface-mountable package in the industry’s smallest class.
To successfully make this KP-2 two-tone PD smaller, the indium-gallium-arsenide photodiodes were laid down in pits arranged on the base for the silicon photodiodes, which ordinarily allows light to pass through. This allowed for the package height to be as low as possible. (Patents have been filed.)
Compared to earlier products from Kyoto Semiconductor, the volume ratio has been reduced to 1/8.
See the following for more information. (https://www.kyosemi.co.jp/en/lp/kpmc29/ )
Samples will be available from August 31, 2020.
Mass production orders will begin on April 1, 2021.
Kyoto Semiconductor
Kyoto Semiconductor was established in 1980 in Kyoto as a dedicated manufacturer of optical semiconductors. The semiconductors manufactured offer superlative performance and precision, suited for use in optical transmission. They are manufactured end-to-end, including pre- and post-processing, and together with Kyoto Semiconductor’s unique packaging technology, at our location in Japan and made available to customers around the world. Kyoto Semiconductor leads the industry with world-standard technologies for optical device solutions based on Japanese quality and attention to production detail.
Company Website: https://www.kyosemi.co.jp/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200525005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
